DRAIC: A Potential Drug Target for Cancer (G145837)

Target Name: DRAIC

NCBI ID: G145837

DRAIC

Other Name(s): downregulated RNA in cancer, inhibitor of cell invasion and migration | Downregulated RNA in cancer, inhibitor of cell invasion and migration

DRAIC: A Potential Drug Target for Cancer

DRAIC (Downregulated RNA in Cancer) is a protein that is expressed in various types of cancer, including breast, lung, and ovarian cancer. It is characterized by a reduction in the levels of RNA, specifically microRNA (miRNA), in the cancer cells . DRAIC has been shown to play a significant role in cancer cell invasion and migration, and as a potential drug target or biomarker, it is of great interest to researchers.

The discovery of DRAIC

DRAIC was first identified as a unique gene expression signature in various types of cancer. The RNA sequencing data revealed that DRAIC was significantly downregulated in cancer cells compared to normal cells. Subsequent studies have shown that DRAIC is highly expressed in various types of cancer, including breast, lung, and ovarian cancer, and that it is associated with poor prognosis.

The function of DRAIC

DRAIC is a protein that is involved in the regulation of gene expression in cancer cells. It is a negative regulator of microRNA (miRNA) levels, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. DRAIC is shown to interact with the miRNA machinery and prevent the binding of miRNAs to their target genes.

DRAIC has been shown to play a role in the regulation of various cellular processes, including cell cycle progression, apoptosis, and angiogenesis. It is involved in the regulation of cell division, and has been shown to promote the arrest in the G1 phase of the cell cycle, which is associated with cell growth and progression. DRAIC is also involved in the regulation of cell apoptosis, which is a critical process for the elimination of damaged or dysfunctional cells.

In addition to its role in cell cycle progression, DRAIC is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. DRAIC has been shown to play a role in the regulation of angiogenesis by suppressing the formation of new blood vessels in cancer cells.

DRAIC as a potential drug target

DRAIC has been shown to be a potential drug target in cancer. Its downregulation in cancer cells makes it an attractive target for small molecules that can inhibit its activity. Researchers have shown that inhibitors of DRAIC can inhibit the migration and invasion of cancer cells, leading to a reduction in the survival of cancer patients.

DRAIC has also been shown to be involved in the regulation of cellular processes that are critical for cancer cell survival, such as cell cycle progression and apoptosis. By inhibiting its activity, researchers have shown that DRAIC can be an effective therapy for various types of cancer.

Conclusion

DRAIC is a protein that has been shown to play a critical role in the regulation of gene expression in cancer cells. Its downregulation in cancer cells makes it an attractive target for small molecules that can inhibit its activity. Researchers have shown that inhibitors of DRAIC can inhibit the migration and invasion of cancer cells, leading to a reduction in the survival of cancer patients. Furthermore, DRAIC is involved in the regulation of cellular processes that are critical for cancer cell survival, making it an attractive target for small molecules that can inhibit its activity.

Protein Name: Downregulated RNA In Cancer, Inhibitor Of Cell Invasion And Migration

The "DRAIC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRAIC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets